Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Efficacy Analysis of a Phase III Study Performed in Russia

Abstract

<b><i>Introduction:</i></b> Allergic rhinitis (AR) is a disease which affects >24% of the population in Russia. Triamcinolone acetonide (TAA) is a corticosteroid used for treating AR. This post hoc analysis assesses the efficacy of intranasal TAA in improving perennial AR (PAR) symptom scores over 4 weeks. <b><i>Methods:</i></b> NASANIF (NCT03317015) was a double-blind, parallel-group, multicenter, prospective, non-inferiority, phase III clinical trial in which patients with PAR were randomized (1:1) to receive TAA or fluticasone propionate (FP) over 4 weeks. Our post hoc analysis evaluates weekly change in PAR symptoms using the reflective Total Nasal Symptom Score (rTNSS), overall and for individual symptoms (sneezing, nasal itching, rhinorrhoea, and nasal obstruction). Proportion of patients and time to achieve a ≥50 or ≥75% reduction in rTNSS were assessed. For rTNSS endpoints, a linear mixed-model methodology was used; for time-to-event endpoints, cumulative incidence functions were estimated using the Kaplan-Meier method, in the per-protocol population. <b><i>Results:</i></b> Of 260 patients, 128 each completed the study and were randomized to receive TAA or FP. From baseline to week 4, the changes in total rTNSS were −7.78 (95% CI: −8.1701 to −7.3967; <i>p</i> < 0.001) and −7.52 (−7.9053 to −7.1320; <i>p</i> < 0.001) for TAA and FP, respectively. Individual symptoms improved significantly from baseline. The proportion of patients achieving ≥50 and ≥75% reductions in total rTNSS was 88.0 and 67.2%, respectively in the TAA group. No significant differences were observed between the TAA and FP in any analyses. <b><i>Conclusions:</i></b> TAA produced effective and prolonged improvement of PAR symptoms over a 4-week treatment period.

Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study

“…Previous trials have shown that TAA is effective in reducing these symptoms in patients with AR [9,17], and the results of our post hoc analysis are consistent with these findings. Furthermore, we have shown that TAA provides effective and prolonged improvement of PAR symptoms in another post hoc analysis of the same trial (Karaulov et al [18], submitted).…”

Efficacy of acupoint injection in the treatment of chronic eczema and its influence on peripheral blood T cells

“…Acupoint injection is a modified TCM treatment that combines acupuncture stimulation with the properties of Western drugs and their penetrating effects on acupoints, exerting a comprehensive therapeutic effect[ 27 ]. Triamcinolone acetonide is a long-acting glucocorticoid with potent and lasting anti-inflammatory and anti-allergic effects[ 28 ]. Local injection can inhibit the transformation of B cells into plasma cells and interfere with humoral immunity[ 29 ] Furthermore, it stabilizes the lysosomal membrane, inhibits leukocytes and macrophages from migrating outside the blood vessels, and reduces inflammation[ 30 ].…”

Интраназальный Триамцинолона Ацетонид Эффективно Облегчает Назальные Симптомы И Улучшает Качество Жизни Пациентов С Круглогодичным Аллергическим Ринитом

“…Было показано, что оба варианта лечения эффективно снижали балльную оценку rTNSS [2]. В двух недавних публикациях были представлены результаты ретроспективного анализа эффективности [3] и качества жизни (КЖ) [4] в течение 28-дневного курса обоих вариантов лечения.…”

“…В посвященной вопросам эффективности ретроспективной публикации еженедельно оценивались изменения в значениях rTNSS для суммарной балльной оценки (диапазон: 0-16) и для каждого из ее четырех компонентов, а также процентная доля пациентов, сообщавших об уменьшении симптомов не менее чем на 50% или 75% [3]. Как суммарная балльная оценка (Рис.…”